BRYOSTATIN COMPOUNDS FOR ENHANCEMENT OF IMMUNOTHERAPY

Provided herein is the use of bryostatin agents to selectively enhance expression, translocation and/or cell surface presentation of an antigen in target cells of interest to modulate immunogenicity of the target cells. Aspects of the methods include, administering an effective amount of a bryostati...

Full description

Saved in:
Bibliographic Details
Main Authors WENDER, Paul, HARDMAN, Clayton, SHIMIZU, Akira J
Format Patent
LanguageEnglish
French
German
Published 21.06.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Provided herein is the use of bryostatin agents to selectively enhance expression, translocation and/or cell surface presentation of an antigen in target cells of interest to modulate immunogenicity of the target cells. Aspects of the methods include, administering an effective amount of a bryostatin agent to a subject to modulate immunogenicity of target cells. The subject methods include a method of treating cancer, including administering to a subject an effective amount of a bryostatin agent to enhance cell surface antigen or neoantigen presentation on target cells of the subject, and administering to the subject a therapeutically effective amount of a therapeutic agent that specifically binds the cell surface antigen to treat the subject for cancer. Aspects of the subject methods also include use of the bryostatin agents to sensitize the target cells to clearance by the subject's immune system.
Bibliography:Application Number: EP20200810391